Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/130452
Full metadata record
DC FieldValueLanguage
dc.creatorCosta, M.
dc.creatorRosa, F.
dc.creatorRibeiro, T.
dc.creatorHernandez-Bautista, R.
dc.creatorBonaldo, M.
dc.creatorSilva, N.G.
dc.creatorEiríksson, F.
dc.creatorThorsteinsdóttir, M.
dc.creatorUssar, S.
dc.creatorUrbatzka, R.
dc.date.accessioned2020-12-04T15:17:20Z-
dc.date.available2020-12-04T15:17:20Z-
dc.date.issued2019
dc.identifier.issnISSN 1660-3397
dc.identifier.urihttps://hdl.handle.net/10216/130452-
dc.description.abstractObesity is a complex disease resulting in several metabolic co-morbidities and is increasing at epidemic rates. The marine environment is an interesting resource of novel compounds and in particular cyanobacteria are well known for their capacity to produce novel secondary metabolites. In this work, we explored the potential of cyanobacteria for the production of compounds with relevant activities towards metabolic diseases using a blend of target-based, phenotypic and zebrafish assays as whole small animal models. A total of 46 cyanobacterial strains were grown and biomass fractionated, yielding in total 263 fractions. Bioactivities related to metabolic function were tested in different in vitro and in vivo models. Studying adipogenic and thermogenic gene expression in brown adipocytes, lipid metabolism and glucose uptake in hepatocytes, as well as lipid metabolism in zebrafish larvae, we identified 66 (25%) active fractions. This together with metabolite profiling and the evaluation of toxicity allowed the identification of 18 (7%) fractions with promising bioactivity towards different aspects of metabolic disease. Among those, we identified several known compounds, such as eryloside T, leptosin F, pheophorbide A, phaeophytin A, chlorophyll A, present as minor peaks. Those compounds were previously not described to have bioactivities in metabolic regulation, and both known or unknown compounds could be responsible for such effects. In summary, we find that cyanobacteria hold a huge repertoire of molecules with specific bioactivities towards metabolic diseases, which needs to be explored in the future.
dc.description.sponsorshipThis work was financed by national funds through FCT (Portugal), BMBF (Germany), Rannis (Iceland) and Formas (Sweden), within the framework of the European ERA-NET Marine Biotechnology project “CYANOBESITY - Cyanobacteria as a source of bioactive compounds with effects on obesity and obesity-related co-morbidities”. The research was additionally supported by the FCT strategic fund UID/Multi/04423/2019. Ralph Urbatzka and Tiago Ribeiro were supported by FCT grants SFRH/BPD/112287/2015 and SFRH/BD/139131/2018 respectively. SU received additional funding from the project Aging and Metabolic Programming (AMPro).
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofMarine Drugs 2019, 17(5), 280
dc.rightsopenAccess
dc.subjectAnti-obesity drugs
dc.subjectBioactivity screening
dc.subjectCyanobacteria
dc.subjectDiabetes
dc.subjectFatty liver disease
dc.subjectMetabolite profiling
dc.subjectUncoupling protein 1
dc.subjectZebrafish Nile red fat metabolism assay
dc.titleIdentification of cyanobacterial strains with potential for the treatment of obesity-related co-morbidities by bioactivity, toxicity evaluation and metabolite profiling
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoCentro Interdisciplinar de Investigação Marinha e Ambiental
dc.identifier.doihttps://doi.org/10.3390/md17050280
dc.relation.publisherversionhttps://www.mdpi.com/1660-3397/17/5/280
Appears in Collections:CIIMAR - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
Costa_M_2019.pdf2.19 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.